Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

High-BMI at diagnosis is associated with inferior survival in patients with osteosarcoma: a report from the Children's Oncology Group.

Altaf S, Enders F, Jeavons E, Krailo M, Barkauskas DA, Meyers P, Arndt C.

Pediatr Blood Cancer. 2013 Dec;60(12):2042-6. doi: 10.1002/pbc.24580.

PMID:
23955975
2.

Poor survival for osteosarcoma of the pelvis: a report from the Children's Oncology Group.

Isakoff MS, Barkauskas DA, Ebb D, Morris C, Letson GD.

Clin Orthop Relat Res. 2012 Jul;470(7):2007-13. doi: 10.1007/s11999-012-2284-9.

3.

Presentation and Long-term Outcome of High-grade Osteosarcoma: A Single-institution Experience.

Berlanga P, Cañete A, Díaz R, Salom M, Baixauli F, Gómez J, Llavador M, Castel V.

J Pediatr Hematol Oncol. 2015 Jul;37(5):e272-7. doi: 10.1097/MPH.0000000000000270.

PMID:
25374283
4.

High BMI at diagnosis is not associated with inferior survival in patients with osteosarcoma. A report from the Cooperative Osteosarcoma Study Group.

Bielack S, Kevric M.

Pediatr Blood Cancer. 2014 May;61(5):952. doi: 10.1002/pbc.24817. No abstract available.

PMID:
24127430
5.

High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.

Boye K, Del Prever AB, Eriksson M, Saeter G, Tienghi A, Lindholm P, Fagioli F, Skjeldal S, Ferrari S, Hall KS.

Pediatr Blood Cancer. 2014 May;61(5):840-5. doi: 10.1002/pbc.24868.

PMID:
24254749
6.

Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children's Oncology Group.

Hingorani P, Seidel K, Krailo M, Mascarenhas L, Meyers P, Marina N, Conrad EU, Hawkins DS.

Pediatr Blood Cancer. 2011 Dec 1;57(6):939-42. doi: 10.1002/pbc.23129.

7.

Response to "High BMI at diagnosis is associated with inferior survival in patients with osteosarcoma".

Altaf S, Enders F, Krailo M, Barkauskas D, Meyers P, Arndt C.

Pediatr Blood Cancer. 2014 May;61(5):951. doi: 10.1002/pbc.24816. No abstract available.

PMID:
24127421
8.

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE; Children's Oncology Group..

J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095.

PMID:
18235123
9.

Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group.

Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P; Children's Oncology Group..

J Clin Oncol. 2007 May 20;25(15):2057-62.

PMID:
17513810
10.

Osteosarcoma developed in the period of maximal growth rate have inferior prognosis.

Lee JA, Kim MS, Kim DH, Lim JS, Park KD, Song WS, Lee SY, Jeon DG.

J Pediatr Hematol Oncol. 2008 Jun;30(6):419-24. doi: 10.1097/MPH.0b013e318168e7dc.

PMID:
18525457
11.

Nutritional status of children and young adults with Ewing sarcoma or osteosarcoma at diagnosis and during multimodality therapy.

Tenardi RD, Frühwald MC, Jürgens H, Hertroijs D, Bauer J.

Pediatr Blood Cancer. 2012 Oct;59(4):621-6. doi: 10.1002/pbc.24001.

PMID:
22147309
12.

What are the factors that affect survival and relapse after local recurrence of osteosarcoma?

Takeuchi A, Lewis VO, Satcher RL, Moon BS, Lin PP.

Clin Orthop Relat Res. 2014 Oct;472(10):3188-95. doi: 10.1007/s11999-014-3759-7.

13.
14.

Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study.

Urakawa H, Nishida Y, Naruse T, Nakashima H, Ishiguro N.

Clin Orthop Relat Res. 2009 Nov;467(11):2932-8. doi: 10.1007/s11999-009-0814-x.

15.

Does body mass index at diagnosis or weight change during therapy predict toxicity or survival in intermediate risk rhabdomyosarcoma? A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Burke ME, Lyden ER, Meza JL, Ladas EJ, Dasgupta R, Wiegner EA, Arndt CA; Children's Oncology Group Soft Tissue Sarcoma Committee..

Pediatr Blood Cancer. 2013 May;60(5):748-53. doi: 10.1002/pbc.24322.

16.

Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy.

Min D, Lin F, Shen Z, Zheng S, Tan L, Yu W, Yao Y.

Asia Pac J Clin Oncol. 2013 Mar;9(1):71-9. doi: 10.1111/j.1743-7563.2012.01560.x.

PMID:
22897971
17.

Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience.

Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD, Rao BN, Daw NC.

Cancer. 2013 Jul 15;119(14):2645-53. doi: 10.1002/cncr.28111.

18.

Childhood osteosarcoma: multimodal therapy in a single-institution Turkish series.

Ayan I, Kebudi R, Ozger H.

Cancer Treat Res. 2009;152:319-38. doi: 10.1007/978-1-4419-0284-9_17. Review.

PMID:
20213399
19.

Limb versus life: the outcomes of osteosarcoma in Cambodia.

Noor S, Thornormóðsson HS, Zervas CT, Ly T, Gollogly J.

Int Orthop. 2014 Mar;38(3):579-85. doi: 10.1007/s00264-013-2173-1.

20.

Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience.

Weiss A, Khoury JD, Hoffer FA, Wu J, Billups CA, Heck RK, Quintana J, Poe D, Rao BN, Daw NC.

Cancer. 2007 Apr 15;109(8):1627-37.

Items per page

Supplemental Content

Support Center